Vim Cancer Research Results

Vim, Vimentin: Click to Expand ⟱
Source:
Type:
Vimentin, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and is known to maintain cellular integrity and provide resistance against stress. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.

In many epithelial-derived tumors (carcinomas), elevated Vimentin expression is often observed in cancer cells that have undergone EMT. This upregulation is characteristic of a shift toward a mesenchymal state, which is associated with reduced cell–cell adhesion and increased motility. Vimentin expression is also noted in the tumor stroma, reflecting the presence and activation of mesenchymal cells such as cancer-associated fibroblasts (CAFs). This dual expression can contribute to the remodeling of the tumor microenvironment.
The degree of Vimentin expression may vary depending on the tumor type, grade, and stage. More aggressive and advanced tumors tend to show higher levels of Vimentin expression.

High Vimentin expression has been correlated with poor clinical outcomes in several cancers, including breast, colorectal, prostate, and lung cancers.
Elevated Vimentin levels are typically associated with higher tumor grade, increased invasiveness, enhanced metastatic potential, and a greater risk of recurrence.
As a component of the EMT signature, high Vimentin expression can serve as an indicator of a more aggressive tumor phenotype and is often associated with reduced overall survival.
- vimentin up-regulation is often used as a marker of EMT in cancer



Scientific Papers found: Click to Expand⟱
9177- ITCs,  SFN,    Dietary Isothiocyanates: Novel Insights into the Potential for Cancer Prevention and Therapy
- Review, Var, NA
CSCs↓, GutMicro↑, Bacteria↓, TumCCA↑, Apoptosis↑, TumAuto↑, angioG↓, TumCI↓, TumMeta↓, NRF2↑, Glycolysis↓, Wnt↓, β-catenin/ZEB1↓, HH↓, NOTCH↓, NK cell↑, EMT↓, angioG↓, BioAv↓, BioAv↑, AntiBio↑, Bacteria↓, HK2↓, PDH↓, OXPHOS↓, AKT1↓, ACC1↓, FASN↓, ACC-α↓, ACLY↓, SREBP1/SREBF1↓, OCT4↓, Nanog↓, YAP/TEAD↓, miR-21↓, miR-29b↓, ALDH1A1↓, miR-140↑, CD44↓, BMI1↓, miR-200c↑, TumCG↓, TumCI↓, TumCMig↓, E-cadherin↑, N-cadherin↓, Vim↓, α-SMA↓, Slug↓, Snail↓, Twist↓, DNAdam⇅, BioAv↓, ChemoSen↑,
1121- JG,    Juglone suppresses epithelial-mesenchymal transition in prostate cancer cells via the protein kinase B/glycogen synthase kinase-3β/Snail signaling pathway
- in-vitro, Pca, LNCaP
E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, GSK‐3β↑,
5115- JG,    Natural Products to Fight Cancer: A Focus on Juglans regia
- Review, Var, NA
Casp3↑, Casp9↑, MMP↓, AR↓, PSA↓, E-cadherin↑, N-cadherin↓, Vim↓, Akt↓, GSK‐3β↓, EMT↑, TumCI↓, MMP9↓, VEGF↓, MMP2↓, TumCCA↑, ROS↑, Apoptosis↑, GSH↓, Catalase↓, SOD↓, GPx↓, DNAdam↑, γH2AX↑, Synergy↑, BAX↑, Fas↑, Pin1↓,
9004- L-THE,    L-theanine suppresses the metastasis of prostate cancer by downregulating MMP9 and Snail
- vitro+vivo, Pca, PC3 - in-vitro, Pca, DU145
TumCI↓, TumCMig↓, EMT↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, E-cadherin↑, ERK↓, NF-kB↓, TumMeta↓, Dose↝, Dose↝,
8236- LE,    Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects
- Review, Var, NA
Bcl-2↓, CDK2↓, PI3K↓, cJun↓, mTOR↓, NF-kB↓, VEGF↓, MMP3↓, toxicity↓, Dose↑, chemoP↑, *antiOx↑, *Inflam↓, Dose↝, *COX2/PTGS2↓, *iNOS↓, *IL6↓, *IL10↓, *PGE2↓, *IκB?, *NRF2↑, *HO-1↑, *lipid-P↓, *ROS↓, *Catalase↑, *GPx↑, *SOD↑, Apoptosis↑, ROS↑, TumCP↓, TumCCA↑, cycE/CCNE↓, cycD1/CCND1↓, p‑GSK‐3β↓, PI3K↓, MKK4↓, MKK7↓, HSP90↓, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1/ATG6↑, p62↓, p‑Akt↓, cl‑Casp9↑, cl‑Casp7↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Cyt‑c↑, P53↑, STAT3↓, E-cadherin↑, Vim↓, N-cadherin↓, CD31/PECAM-1↓, Hif1a↓, iNOS↓, DNAdam↑, MMP↓, BIM↑, APAF1↑, PCNA↓, toxicity↝, eff↑,
2905- LT,    Luteolin blocks the ROS/PI3K/AKT pathway to inhibit mesothelial-mesenchymal transition and reduce abdominal adhesions
- in-vivo, Nor, HMrSV5
*ROS↓, *p‑Akt↓, *Vim↓, *E-cadherin↑, *PI3K↓,
2912- LT,    Luteolin: a flavonoid with a multifaceted anticancer potential
- Review, Var, NA
ROS↑, TumCCA↑, TumCP↓, angioG↓, ER Stress↑, mtDam↑, PERK↑, ATF4↑, eIF2α↑, cl‑Casp12↑, EMT↓, E-cadherin↑, N-cadherin↓, Vim↓, *neuroP↑, NF-kB↓, PI3K↓, Akt↑, XIAP↓, MMP↓, Ca+2↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, Cyt‑c↑, IronCh↑, SOD↓, *ROS↓, *LDHA↑, *SOD↑, *GSH↑, *BioAv↓, Telomerase↓, cMyc↓, hTERT/TERT↓, DR5↑, Fas↑, FADD↑, BAD↑, BOK↑, BID↑, NAIP↓, Mcl-1↓, CDK2↓, CDK4↓, MAPK↓, AKT1↓, Akt2↓, *Beclin-1/ATG6↓, Hif1a↓, LC3II↑, Beclin-1/ATG6↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP/DDIT3↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1/ATG6↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑, *antiAll↑, *Mucositis↓, *TregCell↑, *Beclin-1/ATG6↓, *PI3K↑, *Akt↑, *mTOR↑,
1100- LT,    Luteolin, a flavonoid, as an anticancer agent: A review
- Review, Var, NA
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, ROS↑, ER Stress↑, mtDam↑, p‑eIF2α↝, p‑PERK↝, p‑CHOP/DDIT3↝, p‑ATF4↝, cl‑Casp12↝,
8378- LT,    Luteolin and its derivatives: modulation of epithelial-mesenchymal transition in fibrosis and cancer
- Review, Var, NA
EMT↓, TGF-β1↓, Smad1↓, PI3K↓, Akt↓, Hippo↝, YAP/TEAD↓, *NRF2↑, *HO-1↑, *ROS↓, E-cadherin↑, ZO-1↑, Vim↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, TCF↓, Zeb1↓, angioG↓, eff↑, ROS↑, mtDam↑, MMP↓, ETC↓,
8384- LT,    Current situation and research progress of luteolin in the treatment of gastrointestinal malignant tumors
- Review, GC, NA
Apoptosis↑, TumAuto↑, TumCCA↑, EMT↓, *ROS↓, *antiOx↑, ROS↑, P53↑, LC3II↑, Beclin-1/ATG6↑, p‑MAP2K1/MEK1↓, p‑ERK↓, BAX↑, cl‑Casp3↑, Bcl-2↓, p‑MAPK↓, DNArepair↓, HMGB1↓, XRCC1↓, ERCC3↑, CycB/CCNB1↓, CDC2↓, p‑CHK1↑, TumCCA↑, TumCP?, Wnt↓, β-catenin/ZEB1↓, miR-384↑, PTN↓, MMP2↓, MMP3↓, MMP9↓, MMP16↓, Ferroptosis↑, GPx4↓, Synergy↑, Ki-67↓, GSH↓, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, NF-kB↓, NOTCH↓, miR-139-5p↑, miR-34a↑, miR-422a↑, miR-107↑, miR-21↓, miR-155↓, miR-224↓, miR-340↓, E-cadherin↑, N-cadherin↓, Vim↓, HK1↓, FOXO1↓, compI↓, compIII↓, compV↓, ETC↓, BioAv↝,
8390- LT,    Luteolin in Inflammatory Bowel Disease and Colorectal Cancer: A Disease Continuum Perspective
- Review, IBD, NA - Review, CRC, NA
*Diff↝, *Inflam↓, *ROS↓, *GutMicro↑, *IBI↑, TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, *BioAv↑, *iNOS↓, *TNF-α↓, *IL6↓, *MDA↓, *lipid-P↓, *antiOx↑, *NRF2↑, *HO-1↑, *NQO1↑, *SOD↑, *Catalase↑, *5HT↓, *TPH1↓, *MAPK↓, *ERK↓, *Inflam↓, cycD1/CCND1↓, CDK4↓, TumCCA↑, Casp3↑, Casp9↑, PI3K↓, Akt↓, p‑Akt↓, p‑mTOR↓, E-cadherin↑, N-cadherin↓, Vim↓,
8401- LT,    Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis
- Review, Var, NA
EMT↓, N-cadherin↓, Vim↓, VEGF↓, VEGFR1↓, MMPs↓, Telomerase↓, NF-kB↓, cMyc↓, Bax:Bcl2↑, Casp3↑, PI3K↓, Akt↓, FOXO3↑, P21↑, p27/CDKN1B↑, cl‑PARP↑, Cyt‑c↑, NOTCH↓, HES1↓, ROS↑, SOD↓, miR-34b-5p↑, Hif1a↓, P21↓, survivin↓, Mcl-1?, Bcl-xL↓, MDM2↓, MMP2↓, MMP9↓, MMP3↓, MMP16↓, miR-384↑, NRF2↓, HO-1↓, angioG↓,
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,
8542- Matr,    Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival Signaling
- vitro+vivo, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, p‑PI3K↓, CHK1↓, p‑Akt↓, Bcl-2↓, MTA1↓, Vim↓, MMP2↓, MMP9↓, γH2AX↑, E-cadherin↑, BAX↑, cl‑Casp3↑, Ki-67↓, TumCG↓,
8530- Matr,    Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial‑mesenchymal transition
- in-vitro, HCC, NA
TumCP↓, TumCMig↓, TumCI↓, E-cadherin↑, Vim↓, MMP2↓, MMP9↓, Snail↓, Slug↓, EMT↓, PIP3↑, PTEN↑, p‑Akt↓,
8560- Matr,    Matrine: A Promising Natural Product With Various Pharmacological Activities
- Review, AD, NA - Review, Stroke, NA - Review, Var, NA
*antiAll↑, *Stroke↓, *AntiArt↑, TumCCA↑, VEGF↓, Apoptosis↑, P53↑, P21↑, PCNA↓, EIF4E↓, TumCP↓, TumCMig↓, IAP1↓, ROS↑, EMT↓, PAX2↓, ER Stress↑, HK2↓, Apoptosis↑, STAT3↓, mtDam↑, HMGB1↓, ChemoSen↑, p‑GSK‐3β↓, P-gp/ABCB1↓, MRP1/ABCC1↓, Vim↓, cycD1/CCND1↓, CDK4↓, GSH↓, SOD↓, mt-Cyt‑c↓, BAX↑, MMP9↓, MMP2↓, E-cadherin↓, N-cadherin↓, FOXO1↓, FOXO3↓, FOXO4↓, PI3K↓, ATF4↑, CHOP/DDIT3↑, *Aβ↓, *RAGE↓, *memory↑, *Learn↑, *cognitive↑, *MDA↓, *SOD↑, *GPx↑, *Catalase↑, *antiAll↑, *AHR↓, *SOCS-3↓, *ICAM-1↓, *ROS↓, cachexia↓, *BACE/β-secretase↓, *NF-kB↓, *TNF-α↓, *IL1β↓,
8555- Matr,    Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review
- Review, Var, NA
*AntiTum↑, *Inflam↓, *Analgesic↑, *AntiViral↑, *Imm↑, *PI3K↑, *Akt↑, *mTOR↑, TumAuto↑, PI3K↓, Akt↓, mTOR↓, Beclin-1/ATG6↑, E-cadherin↑, Vim↓, MMP2↓, MMP9↓, Snail↓, Slug↓, PTEN↑, TumCP↓, TumCMig↓, TumCI↓, ChemoSen↑, ROS↑, uPA↓, p‑ERK↓, cachexia↓, antiD↑, GSK‐3β↓, LC3B-II↑, p62↓, Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, FOXO1↑, FOXO3↑, FOXO4↑, PARP↑, BIM↑, Bcl-2↓, survivin↓, miR-21↓, *HOTAIR↑, *p‑Akt↑, *p‑STAT3↑, *STAT3↑, *ROS↓, Wnt↓, β-catenin/ZEB1↓, NOTCH1↓, JAG1↓, HES1↓, BioAv↝, toxicity↝,
8547- Matr,    Matrine in cancer therapy: antitumor mechanisms and nano-delivery strategies
- Review, Var, NA
*Ingr↝, *AntiTum↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, TumCMig↓, TumCI↓, JPT1/HN1↓, Erlin1↑, LINC01116↓, miR-592↑, ERK↓, JAK↓, STAT3↓, miR-182-5p↓, PI3K↓, Akt↓, Wnt↓, β-catenin/ZEB1↓, Sharpin↓, ROS↓, AMPK↑, mTOR↓, Snail↓, Vim↓, N-cadherin↓, MMP2↓, MMP9↓, E-cadherin↑, PTEN↑, miR-10b-5p↓, GPx4↓, lipid-P↑, Iron↑, Piezo1↑,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
9075- MGF,    Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway
- vitro+vivo, BC, MDA-MB-231
tumCV↓, TumMeta↓, MMP7↓, MMP9↓, EMT↓, β-catenin/ZEB1↓, TumVol↓, TumW↓, TumCP↓, Apoptosis↑, Vim↓, E-cadherin↑,
1782- MLT,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, Synergy↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX/CA9↑, P21↑, p27/CDKN1B↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2/PTGS2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
8675- MLT,    Melatonin combined with antineoplastic drugs or natural products for cancer treatment: An update
- Review, Var, NA
ChemoSen↑, TumCP↓, TumCMig↓, CSCs↓, MDR1↓, chemoP?, IL1β↓, IL6↓, IL8↓, TNF-α↓, COX2/PTGS2↓, iNOS↓, Bcl-2↓, Mcl-1↓, IAP1↓, survivin↓, PCNA↓, Ki-67↓, CC(CDKs/cyclins)↓, TumCMig↓, TumCI↓, Fibronectin↓, Vim↓, N-cadherin↓, MMP2↓, MMP9↓, Synergy↑, Synergy↑, OCT4↓, Nanog↓, ERCC1↓, P-gp/ABCB1↓, EMT↓, Synergy↑, ChemoSen↑,
8885- MOR,    Anti-Inflammatory and Anti-Migratory Effects of Morin on Non-Small-Cell Lung Cancer Metastasis via Inhibition of NLRP3/MAPK Signaling Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
IL1β↓, IL18↓, IL6↓, TumCMig↓, TumCI↓, MMP2↓, MMP9↓, uPAR↓, uPA↓, EMT↓, Fibronectin↓, N-cadherin↓, Vim↓, NLRP3↓, MAPK↓,
1129- NarG,    Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity
- in-vitro, Pca, PC3
E-cadherin↓, Vim↓, Snail↓, Twist↓, EMT↓, uPA↓,
1130- OA,    Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-κB Signaling Pathway in Human Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCI↓, TumCMig↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓,
4630- OLE,    Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles
- in-vitro, BC, NA
Bcl-2↓, BAX↑, Casp3↑, Casp9↑, Vim↓, Slug↓, E-cadherin↑, CSCs↓, P21↑, survivin↝, OCT4↑, Nanog↑, SOX4↑,
3257- PBG,    The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review
- Review, Var, NA
CDK4↓, CDK6↓, pRB↓, ROS↓, TumCCA↑, P21↑, PI3K↓, Akt↓, EMT↓, E-cadherin↑, Vim↓, *COX2/PTGS2↓, *MPO↓, *MDA↓, *TNF-α↓, *IL6↓, *Catalase↑, *SOD↑, *AST↓, *ALAT↓, *IL1β↓, *IL10↓, *GPx↓, *TLR4↓, *Sepsis↓, *IFN-γ↑, *GSH↑, *NRF2↑, *α-SMA↓, *TGF-β↓, *IL5↓, *IL6↓, *IL8↓, *PGE2↓, *NF-kB↓, *MMP9↓,
1673- PBG,    An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms
- Review, Var, NA
TumCP↓, Apoptosis↑, TumCCA↑, MALAT1↓, P53↑, RadioS↑, OS↑, ROS↑, NF-kB↓, p65↑, MMP↓, ROS↑, MMP9↓, β-catenin/ZEB1↓, Vim↓, E-cadherin↓, VEGF↓, EMT↓,
4926- PEITC,    PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT
- in-vitro, CRC, SW48
TumCI↓, TumCMig↓, EMT↓, Smad1↓, AntiCan↑, Snail↓, Slug↓, Zeb1↓, ZEB2↓, TGF-β1↓, Synergy↑, E-cadherin↑, N-cadherin↓, Vim↓,
9011- Phyco,    Phycocyanin: A Potential Drug for Cancer Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *Imm↑, *RenoP↑, *hepatoP↑, Synergy↑, EMT↓, TumCCA↑, P21↑, cycE/CCNE↓, CDK2↓, Cyt‑c↑, Casp↑, cl‑PARP1↑, Bax:Bcl2↑, MMP↓, ROS↑, CD59↑, Fas?, IL1β↓, IL2↓, IFN-γ↓, TNF-α↓, JAK3↓, STAT3↓, IL4↑, COX2/PTGS2↓, PGE2↓, MMP9↓, MMP2↓, MMP9↓, TIMP2↓, Vim↓, COL1↓, E-cadherin↑, MDR1↓, AP-1↓, ChemoSen↑, chemoP↑, RadioS↑, TumAuto↑,
1257- PI,    Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways
- ex-vivo, LiverDam, NA
*Fibronectin↓, *α-SMA↓, *COL1↓, *COL3A1↓, *TGF-β↓, *EMT↓, *MMP2↓, *α-SMA↓, *Smad7↑, *E-cadherin↑, *Vim↓, *hepatoP↑, *antiOx↑, *GSH↑, *ROS↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP/DDIT3↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
5163- PLB,    Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells
- in-vitro, SCC, SCC25
TumCP↓, NRF2↓, TumCCA↑, EMT↓, CSCs↓, eff↓, ROS↑, CycB/CCNB1↓, CDK1↓, CDK2↓, CDC25↓, Vim↓, OCT4↓, SOX2↓, Nanog↓, BMI1↓, NQO1↓, GSTA1↓, HSP90↓, toxicity↓,
4693- PTS,    Pterostilbene in the treatment of inflammatory and oncological diseases
- Review, Var, NA
BioAv↑, *Inflam↓, *antiOx↑, AntiTum↑, BBB↑, Half-Life↝, *ROS↓, *NRF2↑, *NQO1↑, *HO-1↑, PTEN↑, miR-19b↓, TumCCA↑, ER Stress↑, PERK↑, ATF4↑, CHOP/DDIT3↑, Ca+2↝, EMT↓, NF-kB↓, Twist↓, Vim↓, E-cadherin↑, ChemoSen↑, toxicity∅, toxicity↝,
4700- PTS,    Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-κB/microRNA 448 circuit
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
CSCs↓, NF-kB↓, Twist↓, Vim↓, E-cadherin↑,
4699- PTS,    Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vivo, BC, MDA-MB-231
TumCMig↓, TumCI↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, Zeb1↑, miR-205↑, Src↓, TumCG↓, FAK↓, EMT↓,
4698- PTS,    Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF ‐κ B /microRNA 448 circuit
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
CSCs↓, NF-kB↓, Twist↓, Vim↓, E-cadherin↑, miR-448↑,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2/KDR/Flk1↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2/PTGS2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, Synergy↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, Synergy↑, Synergy↑, Synergy↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
65- QC,    Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB
- in-vitro, BC, NA
HSP27↓, EMT↓, NF-kB↓, Snail↓, Vim↓, E-cadherin↑, CSCs↓,
54- QC,    Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways
- in-vitro, BC, MCF7
EMT↓, E-cadherin↑, Vim↓, MMP2↓, NOTCH1↓, PI3K/Akt↓, PI3k/Akt/mTOR↓, p‑Akt↓, EZH2↓, H3K27ac↓, TumCCA↑, CSCs↓, CDK1↓, CycB/CCNB1↓, Bcl-xL↓, Bcl-2↓, Nanog↓, H3↓,
53- QC,    Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer
- in-vitro, BC, MDA-MB-231 - NA, NA, MDA-MB-468
E-cadherin↑, Vim↓, cycD1/CCND1↓, cMyc↓, EMT↓, TumCG↓, TumCMig↓, β-catenin/ZEB1↓, ChemoSen↑,
95- QC,    Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent
- in-vitro, Pca, PC3
p‑ERK↓, p‑STAT3↓, p‑Akt↓, N-cadherin↓, Vim↓, cycD1/CCND1↓, Snail↓, Slug↓, Twist↓, PCNA↓, EGFR↓, chemoPv↑,
80- QC,    Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway
- in-vitro, Pca, PC3
Vim↓, ERK↓, Snail↓, Slug↓, Twist↓, EGFR↓, p‑Akt↓, EGFR↓, N-cadherin↓, TumMeta↓, EMT↓,
77- QC,  EGCG,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, CD44+ - in-vitro, NA, CD133+ - in-vitro, NA, PC3 - in-vitro, NA, LNCaP
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Vim↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, TCF↓, eff↑, CSCs↓, TumCG↓, tumCV↓,
923- QC,    Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health
- Review, Var, NA
ROS↑, GSH↓, Ca+2↝, MMP↓, Casp3↑, Casp8↑, Casp9↑, other↓, *ROS↓, *NRF2↑, HO-1↑, TumCCA↑, Inflam↓, STAT3↓, DR5↑, P450↓, MMPs↓, IFN-γ↓, IL6↓, COX2/PTGS2↓, IL8↓, iNOS↓, TNF-α↓, cl‑PARP↑, Apoptosis↑, P53↑, Sp1/3/4↓, survivin↓, TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓, cycD1/CCND1↓, Bcl-2↓, BAX↑, PI3K↓, Akt↓, E-cadherin↓, Vim↓, β-catenin/ZEB1↓, cMyc↓, EMT↓, MMP2↓, NOTCH1↓, MMP7↓, angioG↓, TSP-1↑, CSCs↓, XIAP↓, Snail↓, Slug↓, LEF1↓, P-gp/ABCB1↓, EGFR↓, GSK‐3β↓, mTOR↓, RAGE↓, HSP27↓, VEGF↓, TGF-β↓, COL1↓, COL3A1↓,
1047- RES,    Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells
- in-vitro, Lung, H1299 - in-vitro, Lung, A549 - in-vitro, Lung, H460
PD-L1↑, Snail↑, E-cadherin↓, N-cadherin↑, Fibronectin↑, Vim↑, Axin2↓,
878- RES,    Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression
- vitro+vivo, CRC, LoVo
TumMeta↓, E-cadherin↑, Vim↓, TGF-β↓, SMAD2↓, EMT↓, SMAD3↓,

Showing Research Papers: 101 to 150 of 183
Prev Page 3 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 183

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↓, 4,   Catalase↑, 1,   Copper↑, 1,   frataxin↑, 1,   GPx↓, 3,   GPx↑, 1,   GPx4↓, 5,   GSH↓, 10,   GSH↑, 2,   GSH/GSSG↓, 1,   GSR↓, 2,   GSR↑, 1,   ox-GSSG↑, 1,   GSTs↓, 2,   GSTs↑, 2,   HO-1↓, 6,   HO-1↑, 6,   Iron↑, 1,   c-Iron↑, 1,   lipid-P↓, 1,   lipid-P↑, 5,   MDA↓, 1,   MDA↑, 2,   MPO↓, 1,   NQO1↓, 2,   NQO1↑, 2,   NRF2↓, 9,   NRF2↑, 4,   p‑NRF2↓, 1,   PAO↑, 1,   ROS↓, 11,   ROS↑, 62,   ROS⇅, 4,   i-ROS↑, 1,   SOD↓, 10,   SOD↑, 4,   SOD1↓, 2,   SOD1↑, 1,   SOD2↓, 2,   SOD2↑, 1,   Trx1↑, 1,   TrxR↓, 2,   VitC↓, 1,   VitE↓, 1,   xCT/SLC7A11↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

BCR-ABL↓, 1,   CDC2↓, 5,   CDC2↑, 1,   CDC25↓, 4,   compI↓, 1,   compIII↓, 1,   compV↓, 1,   EGF↓, 1,   ETC↓, 2,   mitResp↓, 2,   MKK7↓, 1,   Mortalin↓, 1,   mtDam↑, 8,   OCR↓, 2,   OXPHOS↓, 1,   PDH↓, 1,   PDH↝, 1,   PINK1↑, 1,   SIRT3↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   5LO↓, 3,   ACC↑, 2,   ACC-α↓, 1,   ACC1↓, 1,   ACLY↓, 1,   ACSL4↑, 1,   ALAT↓, 2,   ALAT↝, 1,   AMPK↑, 13,   p‑AMPK↑, 1,   ATP↓, 3,   CAIX/CA9↓, 1,   CAIX/CA9↑, 1,   ECAR↓, 1,   FASN↓, 1,   GlutMet↓, 1,   Glycolysis↓, 7,   GSK‐3β↓, 8,   GSK‐3β↑, 4,   p‑GSK‐3β↓, 3,   HK1↓, 1,   HK2↓, 8,   lactateProd↓, 1,   LDHA↓, 4,   LDL↓, 1,   NADPH↓, 2,   NADPH↑, 1,   PDK1 / PDPK1↓, 4,   p‑PDK1 / PDPK1↓, 2,   PFK↓, 1,   PIP3↑, 1,   PKM2↓, 2,   SIRT1↓, 6,   SIRT1↑, 3,   SIRT2↓, 1,   SREBP1/SREBF1↓, 3,   SSAT↑, 1,   Warburg↓, 3,  

Cell Death(tgid=5) ⓘ

AIF↑, 2,   APAF1↑, 2,   Apoptosis↓, 1,   Apoptosis↑, 43,   ASC↓, 1,   ASK1↑, 1,   BAD↑, 4,   Bak↑, 3,   BAX↓, 1,   BAX↑, 35,   Bax:Bcl2↑, 3,   Bcl-2↓, 40,   Bcl-2↑, 1,   Bcl-xL↓, 11,   BID↓, 1,   BID↑, 3,   BIM↑, 6,   BNIP3↑, 1,   BOK↑, 1,   Casp↑, 10,   Casp1↓, 1,   Casp10↑, 1,   cl‑Casp12↑, 1,   cl‑Casp12↝, 1,   Casp3↓, 1,   Casp3↑, 40,   cl‑Casp3↑, 8,   Casp6↑, 1,   Casp7↑, 5,   cl‑Casp7↑, 1,   Casp8↑, 7,   cl‑Casp8↑, 1,   Casp9↓, 1,   Casp9↑, 26,   cl‑Casp9↑, 3,   proCasp9↓, 1,   CellShr↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 26,   mt-Cyt‑c↓, 1,   Diablo↑, 6,   DR5↑, 10,   FADD↑, 2,   Fas?, 1,   Fas↑, 10,   FasL↑, 1,   Ferroptosis↑, 5,   HEY1↓, 1,   IAP1↓, 3,   iNOS↓, 8,   JWA↑, 1,   Mcl-1?, 1,   Mcl-1↓, 11,   MDM2↓, 3,   MDM2↑, 2,   p‑MDM2↓, 1,   MOMP↑, 1,   NAIP↓, 1,   NOXA↑, 1,   p38↓, 2,   p38↑, 3,   p‑p38↓, 3,   p‑p38↑, 1,   PUMA↓, 1,   PUMA↑, 2,   survivin↓, 17,   survivin↝, 1,   TNFR 1↑, 2,   TRAIL↑, 2,   TRAILR↑, 1,   TumCD↓, 1,   TumCD↑, 2,   XIAP↓, 12,   YAP/TEAD↓, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 50,   Akt↑, 2,   p‑Akt↓, 19,   AKT1↓, 2,   Akt2↓, 1,   CIP2A↓, 1,   CK2↓, 2,   cMET↓, 3,   p‑cMET↓, 1,   cSrc↓, 1,   EGFR↓, 16,   EGFR↑, 1,   p‑EGFR↓, 1,   ERK↓, 13,   ERK↑, 1,   p‑ERK↓, 9,   FGFR1↓, 2,   FGFR2↓, 1,   GRB2↓, 1,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   HGF/c-Met↓, 1,   Hippo↝, 1,   IGF-1R↓, 2,   p‑IGFR↓, 1,   IKKα↓, 4,   IKKα↑, 1,   p‑IκB↓, 1,   JAK↓, 1,   p‑JAK↓, 1,   JAK1↓, 1,   JAK2↓, 3,   p‑JAK2↓, 1,   JAK3↓, 1,   p‑JAK3↓, 1,   JNK↓, 1,   JNK↑, 3,   p‑JNK↓, 1,   p‑JNK↑, 1,   p‑MAP2K1/MEK1↓, 1,   MAPK↓, 10,   MAPK↑, 7,   p‑MAPK↓, 1,   MARK4↓, 1,   MEK↓, 1,   MKK4↓, 1,   mTOR↓, 31,   mTOR↑, 1,   p‑mTOR↓, 5,   mTORC2↓, 1,   p42↑, 1,   p‑p42↓, 1,   p70S6↓, 1,   P70S6K↓, 2,   PDGFR-BB↓, 1,   PI3K↓, 37,   p‑PI3K↓, 2,   p‑PI3K↑, 1,   PI3K/Akt↓, 2,   PI3k/Akt/mTOR↓, 1,   PIAS-3↑, 1,   PKCδ↓, 2,   PTEN↓, 2,   PTEN↑, 13,   Raf↓, 1,   RAS↓, 1,   Sp1/3/4↓, 5,   Src↓, 2,   p‑Src↓, 1,   STAT↓, 1,   p‑STAT2↓, 1,   STAT3↓, 28,   p‑STAT3↓, 4,   p‑STAT6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF3↑, 1,   ATF4↓, 1,   ATF4↑, 7,   p‑ATF4↝, 1,   cJun↓, 6,   cMyc↓, 21,   DNMT1↓, 4,   DNMT3A↓, 3,   DNMTs↓, 2,   EZH2↓, 5,   FOXM1↓, 2,   FOXO↑, 1,   FOXO1↓, 2,   FOXO1↑, 1,   FOXO3↓, 2,   FOXO3↑, 3,   p‑FOXO3↓, 1,   FOXO4↓, 2,   FOXO4↑, 1,   H3↓, 2,   H3↑, 1,   ac‑H3↑, 1,   H3K27ac↓, 1,   H4↓, 1,   ac‑H4↑, 1,   HATs↓, 1,   HATs↑, 1,   HDAC↓, 6,   HDAC1↓, 3,   HDAC2↓, 2,   HDAC3↓, 1,   HES1↓, 2,   JPT1/HN1↓, 1,   LINC01116↓, 1,   miR-107↑, 1,   miR-10b-5p↓, 1,   miR-126↑, 1,   miR-127-5p↑, 2,   miR-133a-3p↑, 1,   miR-139-5p↑, 2,   miR-140↑, 1,   miR-155↓, 2,   miR-182-5p↓, 1,   miR-19b↓, 2,   miR-200b↑, 1,   miR-200c↑, 2,   miR-203↑, 1,   miR-205↑, 1,   miR-21↓, 3,   miR-210↓, 1,   miR-224↓, 1,   miR-29b↓, 1,   miR-301a-3p↓, 1,   miR-340↓, 1,   miR-34a↓, 1,   miR-34a↑, 1,   miR-34b-5p↑, 1,   miR-384↑, 2,   miR-422a↑, 1,   miR-448↑, 1,   miR-592↑, 1,   MTA2↓, 1,   Myc↓, 2,   NDRG1↑, 2,   OCT4↓, 12,   OCT4↑, 1,   other↓, 1,   other↑, 1,   other↝, 3,   PAX2↓, 1,   SOX2↓, 6,   SOX4↓, 1,   SOX4↑, 1,   SOX9↓, 1,   TCF-4↓, 1,   tumCV↓, 13,   tumCV↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 11,   p‑CHOP/DDIT3↝, 1,   eIF2α↓, 1,   eIF2α↑, 1,   p‑eIF2α↑, 5,   p‑eIF2α↝, 1,   ER Stress↑, 13,   Erlin1↑, 1,   GRP78/BiP↑, 5,   HSF1↓, 1,   HSP27↓, 4,   HSP70/HSPA5↓, 5,   HSP70/HSPA5↑, 1,   HSP90↓, 7,   IRE1↑, 4,   PDI↑, 1,   PERK↑, 5,   p‑PERK↝, 1,   Proteasome↓, 1,   UPR↓, 1,   UPR↑, 2,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG7↑, 1,   Beclin-1/ATG6↓, 2,   Beclin-1/ATG6↑, 9,   LC3‑Ⅱ/LC3‑Ⅰ↓, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3A↑, 1,   LC3B-II↑, 1,   LC3II↓, 1,   LC3II↑, 8,   p62↓, 7,   PARK2↑, 1,   TumAuto↑, 14,   VMP-1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

BRCA1↓, 1,   DFF45↑, 2,   DNAdam↑, 16,   DNAdam⇅, 1,   DNArepair↓, 1,   DNArepair↑, 1,   ERCC1↓, 1,   ERCC3↑, 1,   m-FAM72A↓, 1,   hTERT/TERT↓, 4,   MGMT↓, 1,   p16↑, 1,   P53↓, 1,   P53↑, 29,   p53 Wildtype↑, 1,   PARP↑, 7,   cl‑PARP↑, 17,   PARP1↑, 1,   cl‑PARP1↑, 1,   PCNA↓, 12,   POLD1↓, 1,   RAD51↓, 1,   Telomerase↓, 3,   TOP1↓, 3,   TOP2↓, 4,   TP53↑, 1,   UHRF1↓, 1,   XRCC1↓, 1,   γH2AX↑, 5,   γH2AX↝, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CC(CDKs/cyclins)↓, 1,   CDK1↓, 6,   CDK2↓, 15,   CDK2↑, 2,   CDK4↓, 18,   CDK4↑, 1,   CDK6↓, 10,   CDK6↑, 1,   CHK1↓, 3,   p‑CHK1↑, 1,   Chk2↓, 2,   ChrCon↑, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 4,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 9,   CycB/CCNB1↑, 2,   cycD1/CCND1↓, 28,   cycE/CCNE↓, 7,   E2Fs↓, 1,   E2Fs↑, 1,   Ki-67↓, 11,   MAD↓, 1,   MKI67↑, 1,   P21↓, 1,   P21↑, 21,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 7,   pRB↓, 1,   pRB↑, 1,   RB1↓, 1,   RB1↑, 1,   p‑RB1↓, 1,   Securin↓, 2,   TAp63α↑, 1,   TumCCA↓, 2,   TumCCA↑, 48,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 2,   ALDH1A1↓, 3,   AXIN1↓, 1,   AXIN1↑, 1,   Axin2↓, 1,   BMI1↓, 3,   BMPs↑, 1,   CD133↓, 6,   CD24↓, 1,   CD34↓, 1,   CDX2↓, 1,   cFos↓, 6,   cFos↑, 1,   cMYB↓, 1,   CSCs↓, 28,   CSCs↑, 1,   CSCsMark↓, 1,   EIF4E↓, 1,   FGF↓, 1,   Gli1↓, 4,   HH↓, 2,   IGF-1↓, 2,   IGFBP3↑, 1,   JAG1↓, 1,   Ki-67↓, 11,   Let-7↓, 1,   Let-7↑, 3,   LRP6↓, 3,   p‑LRP6↓, 2,   mTORC1↓, 1,   Nanog↓, 10,   Nanog↑, 1,   Nestin↓, 1,   NKD2↑, 1,   NOTCH↓, 10,   NOTCH1↓, 8,   NOTCH1↑, 1,   NOTCH3↓, 1,   p300↓, 1,   Piezo1↑, 1,   Pirin↓, 1,   SFRP5↑, 1,   Shh↓, 4,   Smo↓, 2,   p‑STAT1↓, 2,   TOPflash↓, 1,   TumCG↓, 28,   TumCG↑, 3,   TumCP?, 1,   TumCP↓, 53,   TumCP↑, 3,   tyrosinase↓, 1,   Wnt↓, 27,   Wnt/(β-catenin)↓, 4,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   AEG1↑, 1,   annexin II↓, 1,   AntiAg↓, 1,   AntiAg↑, 1,   AP-1↓, 4,   AXL↓, 1,   CA↓, 1,   Ca+2↑, 9,   Ca+2↝, 2,   CAFs/TAFs↓, 1,   CCN2/CTGF↓, 1,   Cdc42↓, 1,   CDH1↑, 2,   COL1↓, 5,   COL1A1↓, 3,   COL3A1↓, 1,   COL4↓, 1,   DLC1↑, 1,   E-cadherin↓, 17,   E-cadherin↑, 116,   EMT↓, 113,   EMT↑, 2,   F-actin↑, 1,   FAK↓, 5,   Fibronectin↓, 16,   Fibronectin↑, 1,   ITGA5↓, 1,   ITGA5↑, 3,   ITGB1↓, 2,   ITGB1↑, 3,   ITGB3↓, 1,   LAMA5↑, 3,   LEF1↓, 2,   MALAT1↓, 2,   MET↓, 2,   MET↑, 2,   p‑MET↓, 1,   MMP-10↓, 2,   MMP1↓, 1,   MMP1:TIMP1↑, 1,   MMP13↓, 2,   MMP15↓, 1,   MMP16↓, 2,   MMP2↓, 57,   MMP3↓, 6,   MMP7↓, 6,   MMP9↓, 65,   pro‑MMP9↓, 1,   MMPs↓, 8,   MTA1↓, 1,   N-cadherin↓, 76,   N-cadherin↑, 2,   p44↑, 1,   p‑p44↓, 1,   PDGF↓, 2,   PIR↓, 1,   Rac1↓, 1,   Rho↓, 2,   ROCK1↓, 5,   Sharpin↓, 1,   Slug↓, 37,   Smad1↓, 2,   SMAD2↓, 5,   p‑SMAD2↓, 6,   SMAD3↓, 5,   p‑SMAD3↓, 5,   Snail↓, 68,   Snail↑, 5,   TET1↑, 2,   TGF-β↓, 14,   TGF-β↑, 1,   TGF-β1↓, 2,   TIMP1↓, 2,   TIMP1↑, 2,   TIMP2↓, 2,   TIMP2↑, 1,   TSP-1↑, 3,   TumCI?, 2,   TumCI↓, 66,   TumCMig?, 1,   TumCMig↓, 65,   TumCMig↑, 1,   TumMeta↓, 38,   TumMeta↑, 1,   Twist↓, 24,   Twist↑, 1,   Tyro3↓, 1,   uPA↓, 11,   uPAR↓, 1,   Vim?, 1,   Vim↓, 168,   Vim↑, 7,   Zeb1↓, 24,   Zeb1↑, 4,   ZEB2↓, 3,   ZEB2↑, 1,   α-SMA↓, 2,   α-SMA↑, 1,   β-catenin/ZEB1↓, 52,   p‑β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 27,   angioG↑, 2,   CD31/PECAM-1↓, 1,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 24,   NO↓, 2,   NO↑, 1,   TXA2↓, 1,   VCAM-1↓, 2,   VEGF↓, 37,   VEGFR1↓, 2,   VEGFR2/KDR/Flk1↓, 5,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   CLDN1↓, 4,   CLDN1↑, 1,   CLDN2↓, 1,   CLDN2↑, 1,   CTR1↑, 1,   GLUT1↓, 1,   GLUT1↑, 1,   GLUT3↑, 1,   MMP↓, 32,   MMP↑, 1,   MPT↑, 1,   NHE1↓, 1,   OCLN↑, 1,   ZO-1↑, 9,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   CD44↓, 9,   CD44↑, 1,   CD59↑, 1,   CD8+↑, 1,   COX1↓, 1,   COX2/PTGS2↓, 27,   COX2/PTGS2↑, 1,   CXCL1↓, 1,   CXCL12↓, 1,   CXCR4↓, 8,   DR4↑, 1,   FOXP3↓, 1,   HMGB1↓, 3,   ICAM-1↓, 2,   IFN-γ↓, 2,   Igs↑, 1,   IL1↓, 3,   IL10↓, 4,   IL12↓, 2,   IL12↑, 1,   IL18↓, 1,   IL1β↓, 8,   IL2↓, 1,   IL2↑, 3,   IL4↑, 1,   IL6↓, 19,   IL8↓, 5,   Imm↑, 3,   Inflam↓, 5,   IRAK1↓, 1,   LIF↑, 1,   pol-M1↑, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 48,   NF-kB↑, 1,   NK cell↑, 3,   NLRP3↓, 3,   p50↓, 2,   p65↓, 5,   p65↑, 1,   p‑p65↓, 1,   PD-1↓, 3,   PD-L1↓, 4,   PD-L1↑, 1,   PGE2↓, 10,   PSA↓, 3,   RAGE↓, 1,   SOCS-3↑, 1,   SOCS1↑, 1,   T-Cell↑, 1,   TCF↓, 4,   TCF↑, 1,   Th1 response↑, 3,   Th17↑, 1,   TLR4↓, 1,   TNF-α↓, 8,   TNF-α↑, 2,   TRADD↑, 1,   Treg lymp↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

PTN↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 2,   AR↓, 4,   ER-α36↓, 1,   FGF21↓, 1,   PPARα↓, 1,   PPARα↑, 1,   PPARγ↓, 2,   PPARγ↑, 2,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 10,   BioAv↑, 7,   BioAv↝, 3,   ChemoSen↑, 44,   ChemoSen⇅, 1,   CompStab↝, 1,   CYP1A1↓, 1,   CYP1B1↑, 1,   Dose↑, 2,   Dose↝, 10,   Dose∅, 4,   DrugR↓, 1,   eff↓, 4,   eff↑, 18,   eff↝, 3,   eff∅, 1,   GSTA1↓, 1,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 3,   MDR1↓, 4,   MRP1/ABCC1↓, 1,   P-gp/ABCB1↓, 7,   P450↓, 2,   RadioS↑, 16,   selectivity↑, 13,   Synergy?, 1,   Synergy↑, 41,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   ALAT↝, 1,   ALP↓, 1,   ALP↝, 1,   AR↓, 4,   AST↓, 1,   AST↝, 1,   BRCA1↓, 1,   CEA↓, 1,   CRP↓, 1,   E6↓, 2,   E7↓, 2,   EGFR↓, 16,   EGFR↑, 1,   p‑EGFR↓, 1,   EZH2↓, 5,   FOXM1↓, 2,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 4,   IL6↓, 19,   LDH↓, 3,   Myc↓, 2,   NOS2↓, 1,   NSE↓, 1,   PD-L1↓, 4,   PD-L1↑, 1,   PSA↓, 3,   RAGE↓, 1,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 11,   antiD↑, 1,   antiNeop↑, 1,   AntiTum↓, 1,   AntiTum↑, 7,   cachexia↓, 3,   cardioP↑, 5,   chemoP?, 1,   chemoP↑, 10,   chemoPv↑, 4,   ChemoSideEff↓, 3,   hepatoP↑, 3,   neuroP↑, 2,   OS↑, 4,   Pin1↓, 1,   QoL↑, 2,   radioP↑, 3,   RenoP↑, 3,   Risk↓, 4,   toxicity?, 1,   toxicity↓, 3,   toxicity↑, 1,   toxicity↝, 5,   toxicity∅, 2,   TumVol↓, 5,   TumW↓, 5,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 1,   Bacteria↓, 2,   GutMicro↑, 3,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 4,  
Total Targets: 774

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 17,   Catalase↓, 1,   Catalase↑, 11,   DPPH↓, 1,   GPx↓, 1,   GPx↑, 9,   GSH↑, 9,   GSR↑, 1,   GSTs↑, 2,   HO-1↑, 6,   Iron↓, 1,   Keap1↓, 1,   lipid-P↓, 7,   MDA↓, 6,   MPO↓, 1,   NQO1↑, 2,   NRF2↑, 13,   Prx↓, 1,   Prx↑, 1,   ROS↓, 26,   SOD↑, 13,   SOD2↑, 1,   TAC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   ALAT↓, 2,   ATP↑, 1,   LDHA↑, 1,   NAD↑, 1,   PKM2↓, 1,   SIRT1↑, 4,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Casp3?, 1,   Casp3↓, 3,   Casp9↓, 1,   iNOS↓, 3,   TUNEL↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↑, 2,   p‑Akt↓, 1,   p‑Akt↑, 1,   CREB↑, 1,   ERK↓, 1,   ERK↑, 1,   p‑ERK↓, 1,   IκB?, 1,   JNK↑, 1,   MAPK↓, 1,   mTOR↑, 2,   p‑mTOR↓, 1,   PI3K↓, 1,   PI3K↑, 2,   STAT3↑, 1,   p‑STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑cMyc↑, 1,   HOTAIR↑, 1,   tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↝, 1,   TumCP↓, 1,   tyrosinase↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↝, 1,   cal2↓, 1,   COL1↓, 3,   COL3A1↓, 1,   E-cadherin↑, 6,   EMT↓, 5,   F-actin↓, 1,   Fibronectin↓, 1,   MMP2↓, 1,   MMP9↓, 1,   N-cadherin↓, 1,   Smad7↑, 2,   Snail↓, 1,   Snail↑, 1,   TGF-β↓, 2,   TGF-β1↓, 1,   TIMP1↓, 1,   TregCell↑, 1,   TumCMig↓, 1,   Twist↑, 1,   Vim↓, 9,   Vim↑, 1,   α-SMA↓, 7,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   Hif1a↓, 1,   NO↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,   MMP↑, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 3,   ICAM-1↓, 1,   IFN-γ↑, 1,   IL10↓, 2,   IL10↑, 1,   IL17↓, 1,   IL1β↓, 6,   IL5↓, 1,   IL6↓, 6,   IL8↓, 2,   Imm↑, 2,   Inflam↓, 16,   LPS↓, 1,   NeuroI↓, 1,   NF-kB↓, 3,   PGE2↓, 3,   RAGE↓, 1,   SOCS-3↓, 1,   TLR4↓, 2,   TNF-α↓, 6,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,   AChE↓, 1,   BDNF↑, 1,   TPH1↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 3,   BACE/β-secretase↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AHR↓, 1,   BNP↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 13,   BioAv↑, 1,   BioAv↝, 1,   eff↑, 2,   Half-Life↝, 2,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 3,   BUN↓, 1,   creat↓, 2,   CRP↓, 1,   IL6↓, 6,   RAGE↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Analgesic↑, 1,   AntiAge↑, 1,   antiAll↑, 3,   AntiArt↑, 1,   AntiCan↑, 2,   AntiTum↑, 3,   cardioP↑, 3,   CardioT↓, 1,   chemoP↑, 2,   cognitive↑, 3,   hepatoP↑, 7,   Learn↑, 1,   memory↑, 4,   Mucositis↓, 1,   neuroP↑, 8,   PDE4↓, 1,   RenoP↑, 1,   Stroke↓, 1,   toxicity↓, 6,   toxicity↝, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,   GutMicro↑, 1,   Sepsis↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 161

Scientific Paper Hit Count for: Vim, Vimentin
12 Curcumin
9 Luteolin
8 Quercetin
7 Ashwagandha(Withaferin A)
6 Fisetin
6 Resveratrol
5 EGCG (Epigallocatechin Gallate)
5 Matrine
4 Astragalus
4 Baicalein
4 Pterostilbene
4 Rosmarinic acid
3 Benzyl isothiocyanate
3 Boron
3 Propolis -bee glue
3 5-fluorouracil
3 Diindolylmethane
3 Honokiol
3 Silymarin (Milk Thistle) silibinin
3 Thymoquinone
3 Urolithin
2 Alpha-Lipoic-Acid
2 Apigenin (mainly Parsley)
2 Artemisinin
2 Baicalin
2 Berberine
2 Caffeic acid
2 Centella asiatica / Gotu kola → asiaticoside
2 Chrysin
2 Emodin
2 Garcinol
2 Grapeseed extract
2 HydroxyTyrosol
2 Isorhamnetin
2 Sulforaphane (mainly Broccoli)
2 Juglone
2 Melatonin
2 Ursolic acid
2 Vitamin D3
2 VitK3,menadione
1 1,8-Cineole
1 2-DeoxyGlucose
1 Allyl isothiocyanate
1 Ajoene (compound of Garlic)
1 Allicin (mainly Garlic)
1 Aspirin
1 Betulinic acid
1 Boswellia (frankincense)
1 Butyrate
1 Carvacrol
1 Carnosine
1 Cannabidiol
1 Chlorogenic acid
1 Disulfiram
1 Copper and Cu NanoParticles
1 Ellagic acid
1 Ginkgo biloba-EGb 761
1 Gemcitabine (Gemzar)
1 Eugenol
1 Ferulic acid
1 Sorafenib (brand name Nexavar)
1 Fucoidan
1 Cisplatin
1 Paclitaxel/Taxol
1 Ginkgo biloba
1 Ginkgetin
1 Proanthocyanidins
1 Hydrogen Gas
1 Chemotherapy
1 Hydroxycinnamic-acid
1 phytic acid, Inositol hexakisphosphate
1 Inositol
1 capecitabine
1 Isoliquiritigenin
1 Isothiocyanates
1 L-Theanine
1 Licorice
1 Magnolol
1 Metformin
1 Magnetic Fields
1 Mangiferin
1 Morin
1 Naringin
1 Oroxylin-A
1 Oleuropein
1 Phenethyl isothiocyanate
1 Phycocyanin
1 Piperine
1 Piperlongumine
1 Plumbagin
1 Rutin
1 salinomycin
1 α-Santalol/Sandalwood oil
1 Selenate
1 Shikonin
1 Spirulina(Arthrospira/Limnospira)
1 Taurine
1 Vitamin C (Ascorbic Acid)
1 Zerumbone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:336  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page